Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106


Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity.

Guo H, Singh I, Wang Y, Deane R, Barrett T, Fernández JA, Chow N, Griffin JH, Zlokovic BV.

Eur J Neurosci. 2009 Mar;29(6):1119-30. doi: 10.1111/j.1460-9568.2009.06664.x.


Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity.

Wang Y, Thiyagarajan M, Chow N, Singh I, Guo H, Davis TP, Zlokovic BV.

Stroke. 2009 May;40(5):1864-9. doi: 10.1161/STROKEAHA.108.536680. Epub 2008 Dec 4.


Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity.

Guo H, Wang Y, Singh I, Liu D, Fernández JA, Griffin JH, Chow N, Zlokovic BV.

J Neurochem. 2009 Apr;109(1):116-24. doi: 10.1111/j.1471-4159.2009.05921.x. Epub 2009 Jan 23.


Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1.

Wang Y, Zhao Z, Chow N, Ali T, Griffin JH, Zlokovic BV.

Brain Res. 2013 Apr 24;1507:97-104. doi: 10.1016/j.brainres.2013.02.023. Epub 2013 Feb 21.


Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact.

Walker CT, Marky AH, Petraglia AL, Ali T, Chow N, Zlokovic BV.

Brain Res. 2010 Aug 6;1347:125-31. doi: 10.1016/j.brainres.2010.05.075. Epub 2010 Jun 1.


An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway.

Guo H, Zhao Z, Yang Q, Wang M, Bell RD, Wang S, Chow N, Davis TP, Griffin JH, Goldman SA, Zlokovic BV.

J Neurosci. 2013 Apr 3;33(14):6181-90. doi: 10.1523/JNEUROSCI.4491-12.2013.


Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3.

Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, Fernández JA, Griffin JH, Zlokovic BV.

Neuron. 2004 Feb 19;41(4):563-72.


An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.

Wang Y, Zhang Z, Chow N, Davis TP, Griffin JH, Chopp M, Zlokovic BV.

Stroke. 2012 Sep;43(9):2444-9. doi: 10.1161/STROKEAHA.112.658997. Epub 2012 Jul 17.


Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice.

Wang Y, Sinha RK, Mosnier LO, Griffin JH, Zlokovic BV.

Blood Cells Mol Dis. 2013 Aug;51(2):104-8. doi: 10.1016/j.bcmd.2013.02.009. Epub 2013 Mar 29.


Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke.

Andreou AP, Efthymiou M, Yu Y, Watts HR, Noormohamed FH, Ma D, Lane DA, Crawley JT.

PLoS One. 2015 Apr 1;10(4):e0122410. doi: 10.1371/journal.pone.0122410. eCollection 2015.


Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective.

Cheng T, Liu D, Griffin JH, Fernández JA, Castellino F, Rosen ED, Fukudome K, Zlokovic BV.

Nat Med. 2003 Mar;9(3):338-42. Epub 2003 Feb 3.


3K3A-activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice.

Wang Y, Zhao Z, Rege SV, Wang M, Si G, Zhou Y, Wang S, Griffin JH, Goldman SA, Zlokovic BV.

Nat Med. 2016 Sep;22(9):1050-5. doi: 10.1038/nm.4154. Epub 2016 Aug 22.


Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats.

Wang Y, Zhao Z, Chow N, Rajput PS, Griffin JH, Lyden PD, Zlokovic BV.

Stroke. 2013 Dec;44(12):3529-36. doi: 10.1161/STROKEAHA.113.003350. Epub 2013 Oct 24.


Cytoprotective-selective activated protein C therapy for ischaemic stroke.

Mosnier LO, Zlokovic BV, Griffin JH.

Thromb Haemost. 2014 Nov;112(5):883-92. doi: 10.1160/TH14-05-0448. Epub 2014 Sep 18. Review.


Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C.

Liu D, Cheng T, Guo H, Fernández JA, Griffin JH, Song X, Zlokovic BV.

Nat Med. 2004 Dec;10(12):1379-83. Epub 2004 Oct 31.


Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke.

Williams PD, Zlokovic BV, Griffin JH, Pryor KE, Davis TP.

Curr Pharm Des. 2012;18(27):4215-22.


Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke.

Shibata M, Kumar SR, Amar A, Fernandez JA, Hofman F, Griffin JH, Zlokovic BV.

Circulation. 2001 Apr 3;103(13):1799-805.


2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.

Griffin JH, Mosnier LO, Fernández JA, Zlokovic BV.

Arterioscler Thromb Vasc Biol. 2016 Nov;36(11):2143-2151. Epub 2016 Oct 6. Review.


Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells.

Zhong Z, Ilieva H, Hallagan L, Bell R, Singh I, Paquette N, Thiyagarajan M, Deane R, Fernandez JA, Lane S, Zlokovic AB, Liu T, Griffin JH, Chow N, Castellino FJ, Stojanovic K, Cleveland DW, Zlokovic BV.

J Clin Invest. 2009 Nov;119(11):3437-49. doi: 10.1172/JCI38476. Epub 2009 Oct 19.


Activated protein C N-linked glycans modulate cytoprotective signaling function on endothelial cells.

Ní Ainle F, O'Donnell JS, Johnson JA, Brown L, Gleeson EM, Smith OP, Preston RJ.

J Biol Chem. 2011 Jan 14;286(2):1323-30. doi: 10.1074/jbc.M110.159475. Epub 2010 Nov 2.

Supplemental Content

Support Center